Document is current
Any future updates will be listed below
-
Authors
Yabe, Daisuke https://orcid.org/0000-0002-5334-7687
Matsuhisa, Munehide https://orcid.org/0000-0003-4624-939X
Takahashi, Yoko https://orcid.org/0000-0003-2481-9574
Morimoto, Yukiko
Terauchi, Yasuo https://orcid.org/0000-0002-8872-3697
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000044126 at UMIN JapanDocuments that mention this clinical trial
Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study
https://doi.org/10.1007/s13300-022-01333-w
Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan
https://doi.org/10.1007/s13300-024-01531-8
Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study
https://doi.org/10.1007/s13300-023-01373-w
-
Funding
Funding for this research was provided by:
Sanofi K.K.
- License Information
-
More Information
Article History
Received: 26 October 2023
Accepted: 11 January 2024
First Online: 16 February 2024
Declarations
:
: Daisuke Yabe has received consulting/lecture fees from Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim, Eli Lilly Japan K.K. and Kyowa Kirin Co., Ltd; and grants from Arkray Inc., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim, Taisho Pharmaceutical Co. Ltd. and Terumo Corporation. Munehide Matsuhisa has received honoraria from Sanofi K.K., Takeda Pharmaceutical, Eli Lilly Japan, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Novo Nordisk Pharmaceuticals Ltd., Sumitomo Pharm, Orizuru Therapeutics, Abbott Japan and MSD; research funding from Sysmex and Nissui; and subsidies or donations from Novartis Pharma, Sanofi K.K. and Novo Nordisk Pharmaceuticals Ltd. Yoko Takahashi and Yukiko Morimoto are employees of Sanofi K.K. (and do not hold shares/stock options in the company). Yasuo Terauchi has received honoraria for serving on advisory boards for MSD, Boehringer Ingelheim, Mitsubishi Tanabe Pharma Co., Daiichi Sankyo, Novo Nordisk, Eli Lilly Japan, Sanofi K.K., Astellas Pharma and AstraZeneca; honoraria for lectures from MSD, Ono Pharmaceuticals, Boehringer Ingelheim, Mitsubishi Tanabe Pharma Co., Daiichi Sankyo, Sanwa Kagaku Kenkyusho, Novo Nordisk, Eli Lilly Japan, Sanofi K.K., Sumitomo Pharma Co., Ltd., Shionogi, Bayer Yakuhin, Astellas and AstraZeneca; and research funding from MSD, Ono Pharmaceuticals, Boehringer Ingelheim, Novartis, Takeda, Daiichi Sankyo, Novo Nordisk, Eli Lilly Japan, Sanofi K.K. and Sumitomo Pharma Co., Ltd.
: SPARTA Japan was a retrospective observational study and, as such, compliance with the Declaration of Helsinki 1964 was not required. However, the study protocol for SPARTA Japan was approved on 24 February 2021 by a central ethics committee (Sone Clinic in Tokyo, Japan) for some institutions and by their own institutional ethics committee in other institutions. Written informed consent for the use of participant data was also obtained.
